Grilled meat linked to higher risks for breast cancer patients
Recent findings show that higher consumption of grilled, barbequed, and smoked meat may increase the mortality risk among breast cancer survivors.
Immunotherapy approved for advanced bladder cancer in Europe
Pembrolizumab, an immunotherapy agent, has been approved for some types of locally advanced or metastatic bladder cancer.
Adding radiation to chemotherapy may improve some lung cancer outcomes
For patients with limited metastatic non-small cell lung cancer (NSCLC), adding radiation therapy to chemotherapy with may curb disease progression dramatically.
New treatment for certain metastatic breast cancers approved
The US FDA approved a new treatment for hormone-receptor positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy.
Diet and exercise improve outcomes for obese childhood cancer patients
A study has shown that paediatric cancer patients who are obese may have improved treatment outcomes if they follow a diet and exercise.
Some breast cancer patients may have shorter radiotherapy course
A study showed that a higher-dose, shorter form of radiation is safe, effective, and no more damaging to the breast tissue or skin of breast cancer patients under age 50 than it is in older patients.
Seeking clarity on CT scans after lung cancer surgery
A trial did not show a difference in overall survival (OS) between patients who received computed tomography (CT) scans as part of their follow-up, and those who did not.
Olaparib approved for maintenance ovarian cancer treatment
Olaparib has been approved for maintenance ovarian cancer treatment by the FDA, for women in complete or partial response to platinum-based chemotherapy.
Fertility information and support often lacking
Researchers highlight the lack of information and support around fertility, for many cancer patients who would be candidates for receiving it.
Genetic tests not always done when recommended
Fewer women with history of breast and ovarian cancer take a recommended genetic test. This may increase their risk for additional cancers in the future.
Broader use for fulvestrant approved in some breast cancer types
Fulvestrant has been approved by the FDA for broader use in hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
First gene therapy approved, for acute lymphoblastic leukemia
The US FDA has approved the first gene therapy for use against a type of blood cancer in the United States.
Less breast cancer radiation has better cosmetic outcomes, say 65+ patients
Breast cancer patients aged 65+ reported being more satisfied long term with the cosmetic outcomes of less radiation. However, this should be balanced with a slightly higher recurrence risk.
Combination treatment for HR positive, HER2 positive breast cancer improves outcomes
Adding pertuzumab to a standard regimen for hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer improved progression-free survival in a clinical trial.
A system to cool the scalp may help prevent hair loss for breast cancer patients
In a clinical trial, women diagnosed with stage 1 or 2 breast cancer used a scalp-cooling system while undergoing chemotherapy. The results show that it helped them prevent hair loss.
Improved response to treatment against breast cancer with BRCA mutation
Adding veliparib to carboplatin and paclitaxel chemotherapy improved the overall response rate among patients with locally recurrent or metastatic breast cancer with BRCA1 or BRCA2 mutations.
Combining breast cancer treatments more than double progression free survival
Adding everolimus to fulvestrant more than doubled progression-free survival for women with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy.
FDA approves another use of bevacizumab for treating ovarian cancer
The U.S. FDA has approved bevacizumab for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Combination therapy against HR-positive, HER2-negative advanced breast cancer
Buparlisib, in combination with fulvestrant endocrine therapy, improved outcomes for patients with hormone (HR)-positive advanced breast cancer after treatment with everolimus plus exemestane.
Radiation therapy before breast reconstruction may affect quality of life
Many breast cancer patients will consider breast reconstruction after mastectomy. Radiation therapy can alter the tissue around the breast, impacting reconstruction efforts.
Combination therapy for metastatic breast cancer shows improved survival
Progression-free survival doubled in patients with aromatase inhibitor-resistant metastatic breast cancer treated with everolimus plus fulvestrant vs fulvestrant alone.
Benefits of breast reconstruction after mastectomy do not change much with age
Older women enjoy the same benefits from breast reconstruction following mastectomy for breast cancer as younger women without much higher risk for complications.
Higher vitamin D levels may be linked to better breast cancer outcomes
Breast cancer patients with high vitamin D levels in the blood may have less dangerous tumors and better outcomes. This is according to research within an ongoing study.
New breast cancer drug approved by the European Commission
Palbociclib is now approved in Europe for the treatment of women with hormone receptor-positive, HER2-negative (HR+/HER2-), locally advanced or metastatic breast cancer.
Women with history of depression may have worse outcomes in breast cancer
Women who have a history of depression may have worse survival outcomes, compared to patients without past mental health challenges. This is based on Danish research.
New combination therapy for breast cancer one step closer to approval
Adding palbociclib to letrozole for the treatment of estrogen receptor positive (ER+), HER2-negative (HER2-) advanced breast cancer increased progression-free survival from 14.5 to over 25 months.
Could weight loss help reduce risk of breast cancer recurrence?
Emerging research seems to indicate that women who had breast cancer and maintain a normal weight have lower risk of the cancer coming back.
Some leukemia patients may be able to safely stop their treatment
According to new research, some chronic myeloid leukemia (CML) patients may benefit from stopping their Tyrosine Kinase Inhibitor (TKI) treatments.
Precision medicine contributes in chemotherapy decisions
Precision medicine test in cancer care helps patients and doctors decide if chemotherapy is the proper treatment and what side effects will occur.
Pembrolizumab: A new treatment option for metastatic lung cancer
Pembrolizumab – an anti PD1 therapy- is approved by FDA for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).